Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups | Circulation
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology
Panda Križevci | Krizevci
Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
Panda Križevci | Krizevci
Cipele Valek
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups | Circulation
Increased Small Low-Density Lipoprotein Particle Number | Circulation
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
Panda Križevci | Krizevci
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome | Circulation
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk | Circulation
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk | Circulation
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes
Panda Križevci | Krizevci
